Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Ascending Doses of AZD7503 in Healthy Participants
NCT05143905Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD7503 in Nonalcoholic steatohepatitis (NASH) (10 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with Adverse Events (AEs) at 10 weeks. Started Dec 2021; status: completed.
02
Drugs
AZD7503
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05143905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143905.